As GLP-1 drugs gain popularity for weight loss and improving health, issues arise regarding their affordability and long-term efficacy. A West Virginia subsidy program helped many, but it was abruptly ended, affecting access for low-income individuals. A large study confirms these drugs can reduce kidney disease risk, yet many users fear weight regain post-treatment, prompting experts to advocate for comprehensive lifestyle interventions alongside medication. Most patients express a lack of confidence in maintaining weight loss after stopping the drugs, highlighting the need for sustainable health strategies.